Mayo Clinic researchers are working on developing vaccines that would deliver therapeutic cancer treatment designed to target an individual’s unique tumor characteristics.
BioPharma Diagnostics is offering a new e-guide titled “Finding the right laboratory partner: Top five qualities to support effective scientific research.”
A new FDA-approved test offered by Mayo Clinic Laboratories is expanding testing options for patients with Alzheimer’s disease.
Mayo Clinic Laboratories has developed an assay that offers enhanced detection of the NPM1 genetic mutation that is present in about 30% of patients with acute myeloid leukemia, or AML.
Mayo Clinic Laboratories offers a new test that builds upon the individual NF155 test to help physicians with early diagnosis and treatment optimization.
Yi Lin, M.D., Ph.D., associate professor of medicine at Mayo Clinic and medical director for the Cellular Therapy Program, led a survey to investigate the scope of this problem, which has not been covered in literature thus far. The findings were published as an abstract at the recent annual meeting of the American Society of Clinical Oncology.
Inflammatory bowel disease (IBD) serology testing at Mayo Clinic Laboratories can help physicians distinguish between an ulcerative colitis diagnosis and a Crohn’s disease diagnosis. Melissa Snyder, Ph.D., explains in a “Test in Focus” episode of the “Answers From the Lab” podcast how the IBDP2 serology panel can make this important distinction after first-line testing has failed.
Clinical trials offer expanded treatment for ovarian cancer.
New Mayo Clinic research suggests the use of artificial intelligence can help inform physicians on the selection, use, and dosing of antidepressants for children and adolescents with major depressive disorder.
Researchers find gut microbiome, host gene impact gastrointestinal disorders.
Nikola Baumann, Ph.D., highlights the new NASH-FibroTest, available through Mayo Clinic Laboratories, in a recent “Test in Focus” podcast. The NASH-FibroTest uses three noninvasive tests — NashTest 2, SteatoTest 2, and FibroTest — that allow clinicians to diagnose and make follow-up treatment decisions for patients with nonalcoholic steatohepatitis (NASH).
“NFLC is specific to neurons and usually isn’t found in circulation,” says Alicia Algeciras-Schimnich, Ph.D. “But following neuronal injury, NFLC is released into cerebral spinal fluid and then into blood, where it can be detected.”